CureVac Future Growth

Future criteria checks 3/6

CureVac's revenue is forecast to decline at 5.1% per annum while its annual earnings are expected to grow at 31.7% per year. EPS is expected to grow by 36.1% per annum. Return on equity is forecast to be -16.9% in 3 years.

Key information

31.7%

Earnings growth rate

36.1%

EPS growth rate

Biotechs earnings growth26.7%
Revenue growth rate-5.1%
Future return on equity-16.9%
Analyst coverage

Good

Last updated19 Nov 2024

Recent future growth updates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Recent updates

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Jan 08

Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%

Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%

CureVac: Back To Square One

Oct 08

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

Earnings and Revenue Growth Forecasts

NasdaqGM:CVAC - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272137657N/A1
12/31/2026120-3820N/A4
12/31/202574-9760N/A6
12/31/202453018073N/A5
6/30/202466-278-330-290N/A
3/31/202459-273-312-265N/A
12/31/202354-260-323-268N/A
9/30/202343-302-335-273N/A
6/30/202338-301-325-249N/A
3/31/202350-291-338-249N/A
12/31/202267-249-379-286N/A
9/30/202297-122-527-420N/A
6/30/2022115-219-758-659N/A
3/31/2022117-313-782-673N/A
12/31/2021103-412-861-733N/A
9/30/202168-468-228-109N/A
6/30/202144-361N/AN/AN/A
3/31/202156-219250329N/A
12/31/202049-129475522N/A
9/30/202050-1073662N/A
3/31/202017-102-82-67N/A
12/31/201917-100-99-87N/A
12/31/201813-71-89-74N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CVAC is expected to become profitable in the next 3 years.

Revenue vs Market: CVAC's revenue is expected to decline over the next 3 years (-5.1% per year).

High Growth Revenue: CVAC's revenue is forecast to decline over the next 3 years (-5.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CVAC is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 03:01
End of Day Share Price 2025/01/08 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CureVac N.V. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlie YangBofA Global Research
Geoffrey MeachamBofA Global Research
Martin AusterCredit Suisse